Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ESCHFA25: FINEARTS-HF: Finerenone Risk-Benefit Across Kidney Function
Author(s): Safia Chatur Added: 3 weeks ago
ESC HF 25 - In a FINEARTS HF post-hoc analysis, the relative and absolute effects of finerenone relative to placebo did not significantly differ across kidney function.We are joined by Dr Safia Chatur (Mass General Cardiology, US) to discuss key findings from the FINEARTS-HF trial. This Phase 3 study evaluated the effect of finerenone versus placebo on cardiovascular death and total heart failure… View more

Cardiovascular Renal Metabolic

Heart Failure
Kidney Function Trajectories Before and After HF Hospitalisation
Author(s): Nicolas Girerd Added: 3 weeks ago
ESC HF 25 - Real-world findings suggest kidney function decline could precede heart failure events by up to a year.Prof Nicolas Girerd (University Hospital of Nancy, Nancy, FR) discusses real-world findings from pooled trials EPHESUS, EMPHASIS-HF and BARCELONA. The study investigated if longitudinal changes in kidney function could help identify patients with HFrEF at a higher risk of… View more

Cardiovascular Renal Metabolic

Heart Failure
Dual-pathway Inhibition versus Aspirin Monotherapy
Author(s): Dirk Sibbing , Michael J Blaha , Rajinder Chawla , et al Added: 1 year ago

Anticoagulation

Prevention & Chronic Conditions
PCSK9 Inhibition: The Big Step Forward in Lipid Control
Author(s): Rishi Rikhi , Michael D Shapiro Added: 1 year ago

Vascular Disease and Surgery

Prevention & Chronic Conditions
Antiplatelet Treatment with Dual Pathway Inhibition
Author(s): Tobias Geisler Added: 11 months ago

Anticoagulation

Prevention & Chronic Conditions
HFSA 24: STEP-HFpEF: Exercise Function and Frailty Status
Author(s): Mikhail Kosiborod Added: 8 months ago
HFSA 24 - We are joined virtually by Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss findings from the STEP-HFpEF trial programme in regard to the efficacy of semaglutide according to frailty status, and exercise function at baseline.Interview Questions:1. Could you remind us of the importance of STEP-HFpEF2. What was the study design and patient population?3. What… View more

Heart Failure

Prevention & Chronic Conditions
Maternal Cardiac Function in Pregnancies With Metabolic Disorders
Author(s): Deesha Patel , Makrina D Savvidou Added: 11 months ago

Imaging & Diagnostics

Prevention & Chronic Conditions
Factor XI Inhibition and AF
Author(s): Bianca Rocca , Hugo ten Cate Added: 2 months ago

Anticoagulation

Electrophysiology & Arrhythmia
EuroPCR 25: The REVEAL-AFMR and OCEAN-Mitral Registry
Author(s): Tomohiro Kaneko Added: 3 weeks ago
EuroPCR 25 - Real-world registry findings show transcatheter edge-to-edge repair (TEER) is associated with improved prognosis in patients with atrial functional mitral regurgitation (AFMR).We are joined by Dr Tomohiro Kaneko (Juntendo University Graduate School of Medicine, Tokyo, JP) to discuss outcomes from a retrospective cohort study analysing data from two large-scale Japanese registries,… View more

Intervention
AHA 24: The ENDEAVOR Trial
Author(s): Added: 6 months ago
AHA Conference 2024 - Primary safety and efficacy results from ENDEAVOR investigating the effect of myeloperoxidase inhibition with mitiperstat (AstraZeneca) on symptoms and exercise capacity in patients with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF).Dr Sanjiv Shah (Bluhm Cardiovascular Institute, Chicago, US) joins us onsite at AHA Conference to discuss the… View more

Heart Failure